Health Care · Surgical & Medical Instruments & Apparatus

IRMD IRADIMED CORP SEC Filings & Insider Trading Activity 2026

company
CIK 1325618109 filings
Russell 2000

IRMD at a glance

IRADIMED CORP (IRMD, SEC CIK 1325618) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), IRADIMED CORP (IRMD) reported revenue of $83.8 million (up 14.4% from FY2024) and net income of $22.5 million. Diluted EPS was $1.75.
  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding IRADIMED CORP (IRMD) shares worth $294.8 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by ALLEN MONTY K on September 3, 2026 of 1,014 shares at $86.44 per share.
  • In the last 90 days, IRMD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($123K) on Form 4, a net sale of $123K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$83.8M
+14.4% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$123K
13F holders
26 funds
$294.8M · +0 vs prior quarter
Latest 8-K
Oct 30, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Development and sale of MRI compatible medical devices, notably IV infusion pumps and patient vital signs monitors for safe MRI environment use
  • New product emphasis: MRidium 3870 MRI Compatible IV Infusion Pump System launched in 2025 with Remote Display Unit for control from MRI control room
  • Strategic shift: Discontinuation of older 3860+ infusion pump in 2026, focusing on new 3870 system; expanded intra-hospital use targeting ICU, ER, and critical care units
  • Quantitative metric: 29 U.S. direct sales reps as of Dec 31, 2025; approximately 13,098 pump system channels and 3,397 vital signs monitors sold cumulatively
  • Noteworthy fact: 2025 first commercial shipment of MRidium 3870; only known non-magnetic MRI compatible IV infusion pump operating up to 15,000 gauss magnetic field

Risk Factors

  • FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors
  • Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials
  • Operational risk: single manufacturing facility in Orlando, Florida vulnerable to hurricanes or natural disasters disrupting production and shipments
  • Competitive risk: mature market for 3880 patient monitoring system with competitors offering lower prices threatening revenue and margins
  • Key-person risk: heavy dependence on founder and CEO Roger Susi with no guaranteed succession plan in place

Management Discussion & Analysis

  • Revenue $83.8M in 2025, up 14.4% YoY from $73.2M in 2024, driven by U.S. sales +$10.0M (16.4%) and international sales +$0.6M (4.8%)
  • Operating margin 31.2% in 2025 vs 30.0% in 2024; gross profit margin stable at 77% both years
  • Best segment: MRI Compatible IV Infusion Pump Systems revenue $31.6M (+18.9%), worst: Services and other $3.9M (-4.1%)
  • Cash from operations $24.9M in 2025 vs $25.6M in 2024; capex $8.4M primarily for new facility; financing outflows $17.6M, increased dividend payments and stock unit settlements
  • Management confident liquidity sufficient for 12+ months; plans to monitor capital needs, potential financing, and invest in R&D, marketing, and possible acquisitions

AI summary of the IRMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $24.2M, up 14% YoY from $21.2M, driven by devices, disposables and international sales
  • Vital signs monitoring revenue $8.0M, up from $6.9M, strongest product growth
  • Gross margin 76% vs 78% YoY, pressured by initial new-product production inefficiencies
  • Net margin 26.9% vs 26.3% YoY, with net income $6.5M vs $5.6M
  • Cash $63.3M vs $51.2M; operating cash flow $21.2M vs $19.0M, financing outflow $8.0M from higher dividends
  • Fiscal 2026 outlook: higher revenue and operating expenses, with tariff, supply-chain and geopolitical uncertainty remaining headwinds

Risk Factors

  • No material changes from risks described in the 2025 Annual Report
  • Unknown or currently immaterial risks could materially adversely affect business, financial condition, or future results

AI summary of the IRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 30, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue $24.2M, up 14% YoY, with net income $6.5M, up 17%, signaling strong operating momentum
  • 3870 pump launch gaining traction: over 70% of pump bookings were quad-stack configurations

Item 2.02: Results of Operations and Financial Condition

  • IRADIMED announced financial results for the quarter ended September 30, 2026
  • Exhibit 99.1 contains the detailed earnings release and investor-relevant financial metrics
Filed Aug 18, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces IRADIMED’s financial results for quarter ended June 30, 2026
  • Results available in Exhibit 99.1, enabling investor review of revenue, earnings and guidance details

Item EX-99.1: Item EX-99.1

  • Q2 revenue $20.5M, up 0.5%, but GAAP EPS fell 9% to $0.41 as gross margin declined to 74% from 78%
  • 3870 pump transition underway, with over 70% of new pump orders using four-pump “quad stack” configuration
Filed Jul 31, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces IRADIMED’s financial results for quarter ended June 30, 2026
  • Results and management commentary available in Exhibit 99.1, relevant for assessing operating performance and outlook

Item EX-99.1: Item EX-99.1

  • Q2 revenue $20.5M, up 0.5%, but GAAP EPS fell 9% to $0.41 as gross margin declined to 74% from 78%
  • 3870 pump launch underway, with over 70% of new pump orders selecting the four-pump “quad stack” configuration

AI summaries of IRMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IRMD

Don't miss the next IRMD filing

  • Alerts as it files. A push when IRMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IRMD, by share count.
  • Ask anything. An AI agent that reads every IRMD filing and answers with sources.

IRMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
KIANI JOE EMSep 23, 2026-
KIANI JOE EMSep 23, 2026-
ALLEN MONTY KSellSep 3, 2026$86.44
ALLEN MONTY KSellSep 3, 2026$86.35
GLENN JOHNMJun 20, 2026-
GLENN JOHNFJun 20, 2026$92.20
GLENN JOHNMJun 20, 2026-
Scharen-Guivel Hilda FrederiqueSellJun 4, 2026$95.00

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$73.2M$83.8M
Gross Profit-$56.3M$64.3M
Operating Income-$22.0M$26.1M
Net Income-$19.2M$22.5M
Gross Margin-76.9%76.7%
Op. Margin-30.0%31.2%
Net Margin-26.3%26.8%
Balance Sheet
Total Assets$92.2M$98.3M$108.8M
Equity$71.4M$86.8M$94.6M
ROE-22.2%23.8%
Per Share
EPS-$1.50$1.75
Cash Flow
Operating CF-$25.6M$24.9M
CapEx-$8.0M$7.8M

Source: XBRL data in IRADIMED CORP (IRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IRMD share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IRMD shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$294.8M
Q2 202626$312.3M
Q1 202631$327.8M
Q4 202526$325.9M
Q3 202528$240.6M
Q2 202527$190.9M
Q1 202524$116.2M
Q4 202422$103.6M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IRMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QOct 30, 2026Analysis
8-KOct 30, 2026Analysis-
4Sep 25, 2026--
4Sep 8, 2026--
8-KAug 18, 2026Analysis-
10-QJul 31, 2026Analysis
8-KJul 31, 2026Analysis-
SC 13GJul 28, 2026-
8-KJun 24, 2026Analysis-
4Jun 23, 2026--
4Jun 4, 2026-
4Jun 2, 2026-
4May 28, 2026-
4May 20, 2026-
4May 13, 2026-
4May 6, 2026-
8-KMay 1, 2026Analysis-
10-QMay 1, 2026Analysis
4Apr 30, 2026--
4Apr 22, 2026--
4Apr 15, 2026--
4Apr 7, 2026--
4Apr 1, 2026--
4Mar 25, 2026--
4Mar 18, 2026--

Related Health Care companies

All Health Care →

IRMD SEC filings: frequently asked questions

Are IRMD insiders buying or selling?

In the last 90 days, IRADIMED CORP (IRMD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $122,622 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IRMD stock?

As of September 30, 2026, the largest IRADIMED CORP (IRMD) holders among the 13F filers tracked by SignalX were BlackRock ($82.7 million), Vanguard Capital Management LLC ($31.8 million), Renaissance Technologies LLC ($30.2 million), Two Sigma Investments ($21.3 million), State Street Corp ($20.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IRMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), IRADIMED CORP (IRMD) reported revenue of $83.8 million (up 14.4% from FY2024) and net income of $22.5 million. Diluted EPS was $1.75. The figures come from the XBRL data in the 10-K.

What are the main risks in IRMD's latest 10-K?

In the 10-K filed March 6, 2026, IRADIMED CORP (IRMD) flagged: FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors. Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials. (AI summary of the Risk Factors section.)

What did IRMD report in its latest 8-K?

IRADIMED CORP (IRMD) filed an 8-K on October 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue $24.2M, up 14% YoY, with net income $6.5M, up 17%, signaling strong operating momentum.

What are the latest IRMD SEC filings?

IRADIMED CORP (IRMD) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on October 30, 2026, an 8-K current report on October 30, 2026 and a Form 4 insider filing on September 25, 2026.

What is IRMD's SEC CIK number?

IRADIMED CORP (IRMD)'s SEC Central Index Key (CIK) is 1325618. EDGAR lists every IRMD filing under that number.

Ask anything about IRMD

The research agent reads IRMD's filings, financials, insider trades and 13F holders, then answers with sources.